Subscribe
Sign in
Home
Notes
Archive
Leaderboard
About
When Mechanism Becomes Medicine
Statins, PCSK9, CRISPR, and the Next Wave of Heart Disease Prevention
May 5
•
Katrina Rogers
2
1
1
Latest
Top
Discussions
Deal Screening Mastery (Part 4 of 12): Founder-Problem Fit
Moving Beyond the “Great Team vs Great Idea” Trap
Apr 21
•
Katrina Rogers
2
1
Smart Risk for Smart Science Video Workshop
Leveraging Your Broker as a Strategic Partner
Apr 7
•
Katrina Rogers
1
31:19
Deal Screening Mastery (Part 3 of 12): Fund Fit, Moats, and Milestones
A Qual‑and‑Quant Playbook for Picking Better Deals
Mar 17
•
Katrina Rogers
1
1
The Healthcare Innovation Confidence Gap
Why Hype Outpaces Reality—And How to Close the Gap
Mar 3
•
Katrina Rogers
3
1
Deal Screening Mastery (Part 2 of 12): Stop Winging It on Team Quality
A Practical Framework for Spotting “Great Teams” in Life Sciences
Feb 17
•
Katrina Rogers
2
1
When AI Becomes Drag, Not Lift
The Cost of Broken Integration, Bad Data, and Failed Change
Feb 3
•
Katrina Rogers
4
1
1
Deal Screening Mastery (Part 1 of 12)
Why Commercialization Plans Reveal Founder DNA
Jan 20
•
Katrina Rogers
See all
Thinking Kat
A newsletter for people interested in life science leadership, product, talent, and ecosystem development.
Subscribe
Recommendations
View all 20
The Device Files: From Concept to Commercialization
Blythe Karow
The Biotech Capital Compass
The Biotech Capital Compass
Robert Reich
Robert Reich
Between the Lines
Laura Huang
The Upper Hand with Alison Fragale
Alison Fragale
Thinking Kat
Subscribe
About
Archive
Recommendations
Sitemap
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
